Client portfolio and gene therapeutics pipeline

The Group receives multiple revenue streams from work with clients including licence fees, process development fees and milestones, bioprocessing revenues and royalties on sales once a therapy has reached the market.

We have leveraged our expertise and know-how developed over the last 25 years to build a proprietary pipeline of products in areas where cell and gene therapy has the potential to become an effective treatment intervention. We have reviewed strategic options and we are now exploring external funding opportunities for our therapeutics portfolio.

Note:
*Sio Gene Therapies (Sio) returned the rights to Axo-Lenti-PD to the Group in March 2022. The Group continues to explore outlicensing opportunities for this asset.